fashion -WSS

fashion

author：leisure time 2025-10-01 18:03:38 - browse：7943

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

hotspot

focus

WSS

A new nitrogen execution bill also undermines medical licensing

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Dario to buy mental health app maker Twill in cash and stock deal

UnitedHealth quietly bought dozens of outpatient centers

With psoriasis trial ahead, Alumis raises $259 million

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

focus

fashion

entertainment

State Dept. review finds Biden bears some blame for Afghanistan failures

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Peter Hotez and the public health issue of online harassment

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

The cancer drug shortage isn’t new — and neither are the solutions

A new nitrogen execution bill also undermines medical licensing

Heart attack and stroke risk calculators need revising

Medicare inequities exacerbate Puerto Rico’s health disparities

Trump demands the U.S. pay no more for drugs than other countries … again

How to bring more disabled researchers into academia

explore

Novo Nordisk obesity pill bests Wegovy in early trial

STAT readers on older presidents, polypills, Medicare, and more

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Sen. Paul opposes bill to ban Chinese biotechs

How to bring more disabled researchers into academia

In utero gene editing: an explainer

knowledge

hotspot

focus

entertainment